JPMorgan reports that Sun Pharma plans to appeal a judgment and may seek a settlement with Incyte to expedite its product launch. In a worst-case scenario, the launch could occur post-expiry in December 2026. The firm assigns an NPV of $546 million for Leqselvi, projecting 20% CAGR growth for the specialty business driven by existing products.
| Subscribe To Our Free Newsletter |
